FOLH1 and breast carcinoma: In one of the few published cases of PSMA-based targeted radionuclide therapy in breast cancer, Tolkach et al. shares their experience in treating a young woman with an aggressive triple negative breast cancer that was unresponsive to several conventional lines of therapy.